Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19
Turk J Med Sci
; 51(3): 1675-1681, 2021 08 30.
Article
in English
| MEDLINE | ID: covidwho-1264581
ABSTRACT
Background and aim:
The aim of this study is to evaluate whether the long-term (≥4 weeks) use of proton pump inhibitors (PPIs) is a risk factor for intubation requirement and mortality in patients hospitalized for COVID-19. Materials andmethods:
In this multicentric retrospective study, a total of 382 adult patients (≥18 years of age) with confirmed COVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periods during which they used PPIs the first group included patients who were not on PPI treatment, and the second group included those who have used PPIs for more than 4 weeks.Results:
The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did not use any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR 1.047, 95% CI 1.0261.068), current smoking (HR 2.590, 95% CI 1.3345.025), and PPI therapy for more than 4 weeks (HR 1.83, 95% CI 1.062.41) were found to be independent risk factors for mortality.Conclusion:
The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes for patients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19 treatment.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Proton Pump Inhibitors
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
English
Journal:
Turk J Med Sci
Year:
2021
Document Type:
Article
Affiliation country:
Sag-2103-80
Similar
MEDLINE
...
LILACS
LIS